GERMANTOWN, MARYLAND / ACCESS Newswire / March 4, 2025 / uBriGene Biosciences (uBriGene), a leading cell and gene therapy CDMO, is pleased to announce the submission of its Drug Master File (DMF) for ...

Personalized disease treatment, tailored to an individual’s genetic background, is the future of medicine. Stem cells hold the promise of that objective becoming a reality. A decade ago, the discovery ...

RNA-LNP Based, Non-Viral Delivery - RNA-LNP delivery avoids genome integration risks, leaving no genetic footprint. Optimized for PBMCs - The only non-viral kit proven effective for PBMC reprogramming ...

ROCKVILLE, MD / ACCESS Newswire / June 16, 2025 / uBriGene Biosciences, a leading cell and gene therapy CDMO, is proud to announce the launch of its fully characterized, ready-to-use induced ...

GERMANTOWN, MD / ACCESS Newswire / September 17, 2025 / uBriGene Biosciences, a leader in CGT CDMO and iPSC manufacturing technology development, today announced the launch of its 2nd-Generation iPSC ...

Induced pluripotent stem cells (iPSCs) are derived from adult cells, such as skin or blood cells, which have been “reprogrammed” back to a stem-cell-like state. This transformation grants them the ...

SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of Good Manufacturing Practices (GMP), cutting-edge, induced pluripotent stem cell (iPSC) technologies, today announced the immediate ...

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its ...

Researchers have attained the holy grail of cellular reprogramming: inducing pluripotency without using any DNA-based materials. Using only a cocktail of purified proteins and a chemical additive, ...